In prostate cancer, these genome fusion events, spread over several chromosomes, typically involve the fusion of various genes with genes from the ETS (E-26 Transformation Specific) family of transcription factors, in particular ERG, ETV1, ETV4 and ETV5 genes, and produce “poly-gene” fusion events that can disrupt multiple genes simultaneously and activate oncogenes. Here, ERG is linked to prostate cancer.